Tin tức & Cập nhật

New drug applications approved by US FDA as of 01-15 April 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In the management of statin-treated patients with elevated cholesterol levels, the antisense oligonucleotide targeting angiopoietin-like protein 3 (ANGPTL3) vupanorsen reduces levels of nonhigh-density lipoprotein cholesterol (non-HDL-C) and other lipid parameters, according to the results of TRANSLATE-TIMI 70.

The combination of lenalidomide plus ixazomib in the maintenance treatment of patients with post-transplant myeloma leads to better progression-free survival (PFS) compared with lenalidomide alone in historical controls, according to a study.

Vupanorsen significantly reduces non–high-density lipoprotein cholesterol (non-HDL-C) levels in adults with hyperlipidaemia already taking statins, according to the TRANSLATE-TIMI 70* trial presented at ACC 2022.

Treatment with the combination of tamsulosin plus mirabegron following 125I-brachytherapy for prostate cancer falls short of improving voiding volume compared with tamsulosin monotherapy, although the combination helps with urination frequency and overactive bladder symptoms, according to a study.

First-line treatment with nivolumab – be it in combination with chemotherapy (CT) or with ipilimumab – provided overall survival (OS) benefit and durable responses than CT alone in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to findings from the phase III CheckMate 648 trial.

Getting a heterologous vaccine booster appears to confer a greater protection against COVID-19 than homologous booster, suggest data from a Singapore study.

Patients with head and neck cancer who undergo radiation therapy tend to have persistent opioid use, reveals a study, noting further investigation on early intervention to appropriately wean patients.